Common Use
Glyxambi (empagliflozin/linagliptin) is a combination oral antidiabetic medication prescribed for adults with type 2 diabetes mellitus whose blood sugar levels are not adequately controlled by diet, exercise, or single-agent therapy alone. This powerful dual-action tablet combines two distinct classes of diabetes drugs: empagliflozin, an SGLT2 inhibitor that promotes the excretion of excess glucose through the urine, and linagliptin, a DPP-4 inhibitor that enhances the body's natural incretin-based insulin response while suppressing glucagon release. Together, these mechanisms help lower blood glucose levels through complementary pathways, offering superior glycemic control compared to either component alone. Maintaining proper blood sugar management with Glyxambi reduces the risk of serious diabetes-related complications including cardiovascular disease, kidney damage, nerve damage, and vision loss. If you are looking to buy Glyxambi online, this combination therapy simplifies your diabetes treatment regimen into a single convenient daily tablet.

Dosage and Direction
The recommended dose of Glyxambi is one tablet taken orally once daily in the morning, with or without food, or as specifically directed by your healthcare provider. Available strengths include empagliflozin 10 mg/linagliptin 5 mg and empagliflozin 25 mg/linagliptin 5 mg. Swallow the tablet whole with a full glass of water — do not crush, chew, or break it. Take Glyxambi at the same time each day to maintain consistent blood levels. Do not change the dose or stop taking the medication without first consulting your doctor, as this could lead to uncontrolled blood sugar levels and potential complications.

Precautions
Before starting Glyxambi, inform your doctor if you have kidney disease, liver impairment, low blood pressure, a history of urinary tract infections or genital yeast infections, or if you are prone to dehydration. The SGLT2 inhibitor component increases urinary glucose excretion, which may predispose patients to urinary and genital infections. Monitor blood sugar levels regularly as directed by your healthcare provider. Stay well-hydrated throughout the day to prevent dehydration, particularly during hot weather, exercise, or illness. Avoid driving or operating heavy machinery if you experience dizziness or episodes of low blood sugar (hypoglycemia). Patients over 65 years old should use Glyxambi with additional caution due to increased risk of volume depletion.

Contraindications
Glyxambi is contraindicated in patients with type 1 diabetes mellitus, as it is not effective and potentially dangerous in this population. It should not be used in patients with diabetic ketoacidosis (DKA), severe kidney impairment (eGFR below 30 mL/min), end-stage renal disease, or patients on dialysis. The medication is also contraindicated in individuals with known hypersensitivity to empagliflozin, linagliptin, or any inactive component of the tablet. Pregnant and breastfeeding women should not use Glyxambi without specific medical guidance.

Possible Side Effects
Common side effects of Glyxambi include urinary tract infections, genital yeast infections (particularly in women), increased urination, hypoglycemia (especially when combined with insulin or sulfonylureas), upper respiratory tract infections, headache, and nasopharyngitis. Some patients may experience mild nausea or joint pain. Rare but serious adverse effects include severe dehydration, acute kidney injury, diabetic ketoacidosis (even with normal blood sugar levels — a condition known as euglycemic DKA), necrotizing fasciitis of the perineum (Fournier's gangrene), and severe allergic reactions including anaphylaxis. Seek immediate medical attention if you experience signs of dehydration, unusual fatigue, difficulty breathing, or severe abdominal pain.

Drug Interaction
Glyxambi may interact with insulin and insulin secretagogues (such as sulfonylureas like glimepiride or glipizide), potentially increasing the risk of hypoglycemia — dose adjustments of these medications may be necessary. Diuretics (particularly loop and thiazide diuretics) can compound the volume-depleting effects of empagliflozin, leading to dehydration and low blood pressure. Other medications affecting kidney function should be used cautiously. Rifampin and other strong enzyme inducers may reduce the effectiveness of linagliptin. Always inform your healthcare provider about all prescription drugs, over-the-counter medications, vitamins, and herbal supplements you are currently taking.

Missed Dose
If you miss a dose of Glyxambi, take it as soon as you remember on the same day. If it is already close to the time of your next scheduled dose, skip the missed dose entirely and resume your regular once-daily schedule. Do not take a double dose to make up for a missed one, as this may increase the risk of adverse effects including hypoglycemia and dehydration.

Overdose
An overdose of Glyxambi may cause severe hypoglycemia (low blood sugar), significant dehydration, electrolyte imbalances, or acute kidney problems. Seek immediate emergency medical attention if an overdose is suspected. Treatment is primarily supportive, focusing on correcting blood sugar levels, restoring fluid balance, and monitoring kidney function.

Storage
Store Glyxambi tablets at controlled room temperature between 20°C and 25°C (68°F to 77°F), away from excessive heat, moisture, and direct sunlight. Keep the tablets in their original blister packaging until ready to use. Store out of reach of children and pets. Do not use Glyxambi after the expiration date printed on the package.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.